undamentalytics Newsletter
Sign in

Ispecimen Inc. revenue

Ispecimen Inc.'s revenue was $1.9m in fiscal 2025, down 79.2% on the year before. Since fiscal 2020 ($8.2m) it has grown at a compound -25.1% a year. Over the last twelve months it was $466,302.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8111010920
Growth on the year before—+36.1%−6.6%−4.6%−6.4%−79.2%—
Gross profit566540−0
Gross margin56.2%52.9%54.3%51.9%45.0%11.2%−98.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $1.7M 89.9% ▼ 80.9%
Shipping and Handling $193,998 10.1% ▲ 4.2%

From Ispecimen Inc.'s 10-K filed April 1, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Life Sciences Tools & Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Ispecimen Inc. $466,302 -92.1% -64.1%
YD Bio Ltd $596,817 16.9% —
Quantum-si Inc $1.6m -53.0% 51.8%
Aclarion, Inc. $83,769 33.1% 0.2%
Bionexus Gene Lab Corp $3.1m -67.3% -32.9%
Seer, Inc. $14.2m -12.7% -5.1%

Compare with peers

Head to head: ISPC vs YDESISPC vs QSIACON vs ISPC

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Ispecimen Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ispecimen Inc.